This post was originally published on this site
Novavax Inc. has delayed plans to seek regulatory clearances for its COVID-19 vaccine, while shortages in raw materials are slowing the ramp-up of production of doses, the company said.
The delays may set back efforts to increase vaccinations in developing countries, which have been dealing with limited doses of currently available shots and are looking forward to Novavax’s.
